Compare PLSE & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | CGEM |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 671.7M |
| IPO Year | 2016 | 2021 |
| Metric | PLSE | CGEM |
|---|---|---|
| Price | $14.41 | $9.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $22.00 | ★ $28.00 |
| AVG Volume (30 Days) | 182.7K | ★ 1.5M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $86,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,002.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $5.68 |
| 52 Week High | $25.00 | $13.33 |
| Indicator | PLSE | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 54.34 | 45.34 |
| Support Level | $13.94 | $9.48 |
| Resistance Level | $14.70 | $13.10 |
| Average True Range (ATR) | 0.62 | 0.97 |
| MACD | 0.24 | -0.33 |
| Stochastic Oscillator | 90.56 | 5.39 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.